A CB(2) receptor agonist, A-836339, modulates wide dynamic range neuronal activity in neuropathic rats: contributions of spinal and peripheral CB(2) receptors.

We investigated the systemic and site-specific actions of a selective CB(2) receptor agonist, A-836339 on mechanically evoked (10 g von Frey hair) and spontaneous firing of spinal wide dynamic range (WDR) neurons in neuropathic (L5 and L6 ligations) and sham rats. Systemic administration of A-836339 (0.3-3 micromol/kg, i.v.) reduced both evoked and spontaneous WDR neuronal activity in neuropathic, but not sham rats. The effects in neuropathic rats were blocked by pre-administration of a CB(2), but not a CB(1), receptor antagonist. Similar to systemic delivery, intra-spinal injection of A-836339 (0.3 and 1 nmol) also attenuated both von Frey-evoked and spontaneous firing of WDR neurons in neuropathic rats. Intra-spinal injections of A-836339 were ineffective in sham rats. Application of A-836339 (3-30 nmol) onto the ipsilateral L5 dorsal root ganglion (DRG) of neuropathic rats reduced the von Frey-evoked activity of WDR neurons, but spontaneous firing was unaltered. All effects of A-836339 on WDR neuronal activity following either intra-spinal or intra-DRG administration were blocked by pre-administration of a CB(2) receptor antagonist. Pre-administration of a CB(1) receptor antagonist did not alter the site-specific effects of A-836339. Injection of A-836339 (300 nmol) into the neuronal receptive field on the ipsilateral hind paw did not affect evoked or spontaneous firing of WDR neurons. Thus, the current data demonstrate that modulation of spinal neuronal activity by a CB(2) receptor agonist is enhanced following peripheral nerve injury, and further delineate the contribution of spinal and peripheral CB(2) receptors to this modulation.

P2X7-related modulation of pathological nociception in rats.

Growing evidence supports a role for the immune system in the induction and maintenance of chronic pain. ATP is a key neurotransmitter in this process. Recent studies demonstrate that the glial ATP receptor, P2X7, contributes to the modulation of pathological pain. To further delineate the endogenous mechanisms that are involved in P2X7-related antinociception, we utilized a selective P2X7 receptor antagonist, A-438079, in a series of in vivo and in vitro experiments. Injection of A-438079 (10-300 micromol/kg, i.p.) was anti-allodynic in three different rat models of neuropathic pain and it attenuated formalin-induced nocifensive behaviors. Using in vivo electrophysiology, A-438079 (80 micromol/kg, i.v.) reduced noxious and innocuous evoked activity of different classes of spinal neurons (low threshold, nociceptive specific, wide dynamic range) in neuropathic rats. The effects of A-438079 on evoked firing were diminished or absent in sham rats. Spontaneous activity of all classes of spinal neurons was also significantly reduced by A-438079 in neuropathic but not sham rats. In vitro, A-438079 (1 microM) blocked agonist-induced (2,3-O-(4-benzoylbenzoyl)-ATP, 30 microM) current in non-neuronal cells taken from the vicinity of the dorsal root ganglia. Furthermore, A-438079 dose-dependently (0.3-3 microM) decreased the quantity of the cytokine, interleukin-1beta, released from peripheral macrophages. Thus, ATP, acting through the P2X7 receptor, exerts a wide-ranging influence on spinal neuronal activity following a chronic injury. Antagonism of the P2X7 receptor can in turn modulate central sensitization and produce antinociception in animal models of pathological pain. These effects are likely mediated through immuno-neural interactions that affect the release of endogenous cytokines.

Mapping brain activity following administration of a nicotinic acetylcholine receptor agonist, ABT-594, using functional magnetic resonance imaging in awake rats.

Administration of ABT-594, a potent agonist for nicotinic acetylcholine receptors with selectivity for the alpha4beta2 receptor subtype, is known to modulate a diverse array of behaviors including those associated with nociception, anxiety and motor function. In this study, we sought to gain insight into the neural actions of ABT-594, in vivo, by conducting functional magnetic resonance imaging in awake and anesthetized rats. Using T(2)*-weighted gradient echo imaging and an ultrasmall superparamagnetic iron oxide contrast agent, functional imaging was conducted on a 4.7 T magnet to measure changes in relative cerebral blood volume. In awake, restrained, male Sprague-Dawley rats that were acclimated to the imaging environment, injection of ABT-594 (0.03-0.3 micromol/kg, i.v.) evoked changes to relative cerebral blood volume in several neural regions including the cingulate, somatosensory, motor, auditory, and pre-frontal cortices as well as the thalamus and the periaqueductal gray/dorsal raphe. These effects were typically bimodal with significant decreases in relative cerebral blood volume at the 0.03 micromol/kg dose and increases at the higher doses (0.1 and 0.3 micromol/kg). The decreases and increases in relative cerebral blood volume were often observed within the same region, but triggered by different doses. Both increases and decreases in relative cerebral blood volume were blocked by pretreatment with the noncompetitive nicotinic acetylcholine receptor antagonist, mecamylamine (5 micromol/kg, i.p.) in awake rats. Administration of ABT-594 (0.1 micromol/kg, i.v.) to alpha-chloralose-anesthetized rats did not significantly alter relative cerebral blood volume in any brain region suggesting an anesthetic-related interference with the effects of ABT-594. The neural regions affected by administration of ABT-594 corresponded well to the known pre-clinical behavioral profile for this compound, and demonstrate the utility of using functional magnetic resonance imaging in awake animals to study pharmacological action.

Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist.

BACKGROUND AND PURPOSE: To further assess the clinical potential of the blockade of metabotropic glutamate receptors (mGluR1) for the treatment of pain. EXPERIMENTAL APPROACH: We characterized the effects of A-841720, a novel, potent and non-competitive mGluR1 antagonist in models of pain and of motor and cognitive function. KEY RESULTS: At recombinant human and native rat mGluR1 receptors, A-841720 inhibited agonist-induced calcium mobilization, with IC50 values of 10.7+/-3.9 and 1.0 +/- 0.2 nM, respectively, while showing selectivity over other mGluR receptors, in addition to other neurotransmitter receptors, ion channels, and transporters. Intraperitoneal injection of A-841720 potently reduced complete Freund's adjuvant-induced inflammatory pain (ED50 = 23 micromol kg(-1)) and monoiodoacetate-induced joint pain (ED50 = 43 micromol kg(-1)). A-841720 also decreased mechanical allodynia observed in both the sciatic nerve chronic constriction injury and L5-L6 spinal nerve ligation (SNL) models of neuropathic pain (ED50 = 28 and 27 micromol kg(-1), respectively). Electrophysiological studies demonstrated that systemic administration of A-841720 in SNL animals significantly reduced evoked firing in spinal wide dynamic range neurons. Significant motor side effects were observed at analgesic doses and A-841720 also impaired cognitive function in the Y-maze and the Water Maze tests. CONCLUSIONS AND IMPLICATIONS: The analgesic effects of a selective mGluR1 receptor antagonist are associated with motor and cognitive side effects. The lack of separation between efficacy and side effects in pre-clinical models indicates that mGluR1 antagonism may not provide an adequate therapeutic window for the development of such antagonists as novel analgesic agents in humans.

Antinociceptive properties of a non-nucleotide P2X3/P2X2/3 receptor antagonist.

Acute systemic administration of a novel and highly selective non-nucleotide P2X(3)/P2X(2/3) receptor antagonist, A-317491, has been shown to reduce chronic hyperalgesia and allodynia in several animal models of pathological pain in the absence of cardiovascular and CNS side effects. Furthermore, these studies have also outlined the antinociceptive profile for a P2X(3)/P2X(2/3) receptor antagonist, as A-317491 was effective in models of chronic inflammatory and neuropathic pain, but not in models of acute, acute inflammatory or visceral pain. The development of A-317491 has also added to the current understanding of P2X(3)/P2X(2/3) receptor pharmacology and its contributions to nociceptive transmission and modulation. To this end, recent studies have demonstrated that both spinal and peripheral P2X(3)/P2X(2/3) receptors have significant but differential contributions to nociception in animal models of nerve or tissue injury, and that antagonism of spinal P2X(3)/P2X(2/3) receptors results in an indirect activation of the opioid system to alleviate inflammatory thermal hyperalgesia and chemogenic nociception. Thus, preclinical data have shown considerable promise for the utility of a P2X(3)/P2X(2/3) receptor antagonist to alleviate various forms of chronic pain. Furthermore, the discovery of this selective and metabolic stable antagonist for P2X(3)/P2X(2/3) receptors has also been useful in defining the contributions of these receptors to states of pathological pain.

A selective α2 B adrenoceptor agonist (A-1262543) and duloxetine modulate nociceptive neurones in the medial prefrontal cortex, but not in the spinal cord of neuropathic rats.

BACKGROUND: The noradrenergic system contributes to pain modulation, but the roles of its specific adrenoceptors are still being defined. We have identified a novel, potent (rat EC50 = 4.3 nM) and selective α2B receptor agonist, A-1262543, to further explore this adrenoceptor subtype's contribution to pathological nociception. METHODS: Systemic administration of A-1262543 (1-10 mg/kg, intraperitoneal) dose-dependently attenuated mechanical allodynia in animals with a spinal nerve ligation injury. To further explore its mechanism of action, the activity of nociceptive neurones in the spinal cord and medial prefrontal cortex (mPFC) were examined after injection of 3 mg/kg of A-1262543 (intravenous, i.v.). These effects were compared with duloxetine (3 mg/kg, i.v.), a dual noradrenaline (NA) and serotonin (5-HT) reuptake inhibitor. RESULTS: Systemic administration of A-1262543 or duloxetine did not alter the spontaneous or evoked firing of spinal wide dynamic range and nociceptive-specific neurones in the neuropathic rats, indicating that neither compound engaged spinal, peripheral or descending pathways. In contrast to the lack of effect on spinal neurones, both A-1262543 and duloxetine reduced the evoked and spontaneous firing of 'pain-responsive' (PR) neurones in the mPFC. Duloxetine, but not A-1262543, also inhibited the firing of pain non-responsive (nPR) neurones in the mPFC probably reflecting duloxetine's contribution to modulating non-pain endpoints. CONCLUSIONS: These data highlight that activation of the α2B adrenoceptor as well as inhibiting NA and 5-HT reuptake can result in modulating the ascending nociceptive system, and in particular, dampening the firing of PR neurones in the mPFC.

Relationship between mechano-receptive fields of dorsal horn convergent neurons and the response to noxious immersion of the ipsilateral hindpaw in rats.

This study examines the relationship between mechano-receptive fields (inhibitory and excitatory, located on the ipsilateral hindpaw) of convergent dorsal horn neurons, and the responses of the neurons to noxious immersion of an entire paw in noxious hot water. In pentobarbital anesthetized rats with intact spinal cords and in unanesthetized decerebrate-spinalized rats, rat hindpaws were immersed in 50 degrees C water for 10 s after the mechano-receptive fields had been delineated using 5-s noxious pinches. Convergent neurons were either excited or inhibited by noxious immersion of the hindpaw. In both groups, a significant association (chi2, P < 0.01) was found between the make-up of the mechano-receptive field and the response of the neuron to immersion. Immersion-inhibited neurons (intact = 27, spinalized = 13), always had both an excitatory and an inhibitory mechano-receptive field on the same hindpaw. Additionally, when the hindpaw was removed from the noxious water, these immersion-inhibited cells displayed a strong afterdischarge which was immediately inhibited once the paw was reimmersed. Pinch-induced and immersion-induced inhibition were found in both spinalized and intact rats suggesting spinal mechanisms were sufficient to mediate this effect. The majority of immersion-excited cells showed only an excitatory mechano-receptive field on the hindpaw (intact rats = 18/23 or 78.3%, spinalized rats = 24/36 or 66.7%). However, other immersion-excited cells had both an inhibitory and an excitatory mechano-receptive field on the hindpaw (intact rats = 5/23 or 21.7%, spinalized rats = 12/36 or 33.3%). The response of a convergent neuron, which has its excitatory receptive field located on a paw, to noxious immersion of the entire paw can be predicted by the make-up of the mechano-receptive fields. Additionally, since noxious paw immersion affects ipsilateral convergent neurons in two opposite manners, it suggests that other effects, such as heterotopic actions, might also not be uniform.

Analysis of excitatory amino acid transmission within the rostral ventromedial medulla: implications for circuitry.

Two classes of neurons with distinct responses to opioids have been identified in the rostral ventromedial medulla (RVM), a region with a well-documented role in nociceptive modulation. 'On-cells' are directly inhibited by opioids, and opioids can thus gain access to the modulatory circuitry of the RVM by an action on these neurons. 'Off-cells' are likely to exert a net inhibitory effect on nociceptive processing, and are activated by opioids. Because the opioid activation of off-cells is indirect, it has been proposed that on-cells function as inhibitory interneurons, and that opioid-induced suppression of on-cell firing in turn activates off-cells via disinhibition. The aim of the present study was to test this possibility. We had previously shown that excitatory amino acid (EAA) neurotransmission is crucial to the nocifensor reflex-related on-cell burst. We therefore infused the non-selective EAA receptor antagonist kynurenate (0.5-2 nmol, 200-500 nl) into the RVM while recording activity of on-, off- and neutral cells in lightly anesthetized rats. Kynurenate infusions produced a significant decrease in on-cell firing, with suppression of the on-cell burst. Off-cells nonetheless continued to display a tail flick-related pause in firing. Tail flick latency was used as an index of nociceptive responsiveness, and was unaffected by kynurenate infusions. These results demonstrate that a burst of on-cell firing is not required in order for the off-cell to exhibit a reflex-related pause in discharge, and do not support the proposed crucial role for on-cells as inhibitory interneurons within the RVM. In addition, preferential suppression of on-cell tiring was not associated with an increase in tail flick latency. This suggests that, under the conditions of these experiments, on-cell discharge is not a potent regulator of moment-to-moment variations in nociceptive responsiveness.

The role of excitatory amino acid transmission within the rostral ventromedial medulla in the antinociceptive actions of systemically administered morphine.

Two classes of neurons with distinct responses to opioids have been identified in the rostral ventromedial medulla (RVM), a region with a well-documented role in nociceptive modulation. 'Off-cells' are activated, indirectly, by opioids, and are likely to exert a net inhibitory effect on nociceptive processing. 'On-cells' are directly inhibited by opioids, and there is evidence that these neurons can, under various conditions, facilitate nociception. We showed previously that excitatory amino acid (EAA) neurotransmission is crucial to the nocifensor reflex-related on-cell burst, but plays little role in maintaining the ongoing activity of off-cells. The aim of the present study was to determine whether EAA transmission contributes to the activation of off-cells and the concomitant behavioral antinociception that follow systemic opioid administration. The non-selective EAA receptor antagonist kynurenate was infused into the RVM (1 nmol/200 nl) of lightly anesthetized rats prior to administration of morphine (1.5 mg/kg i.v). Off-cell, on-cell and neutral cell firing, as well as, tail flick response (TF) latencies were recorded. Kynurenate, significantly attenuated the characteristic opioid activation of off-cells. As a group, off-cells in kynurenate-treated animals did not become continuously active, and continued to exhibit tail-flick related pauses in firing. On-cell and neutral cell responses to opioid administration were unchanged. Opioid inhibition of the TF was also reduced, although baseline TF latency was unaffected, by RVM kynurenate. EAA-mediated activation of off-cells, thus has an important role in opioid analgesia. The present observations underscore the importance of excitatory interactions among opioid-sensitive nociceptive modulatory circuits for systemic morphine analgesia, suggesting that such interactions are a critical factor in the synergistic relationships which have been demonstrated among these sites.

Design of adenosine kinase inhibitors from the NMR-based screening of fragments.

A strategy is described for designing high-affinity ligands using information derived from the NMR-based screening of fragments. The method involves the fragmentation of an existing lead molecule, identification of suitable replacements for the fragments, and incorporation of the newly identified fragments into the original scaffold. Using this technique, novel substituents were rapidly identified and incorporated into lead inhibitors of adenosine kinase that exhibited potent in vitro and in vivo activities. This approach is a valuable strategy for modifying existing leads to improve their potency, bioavailability, or toxicity profile and thus represents a useful technique for lead optimization.

Method of analysis of local neuronal circuits in the vertebrate central nervous system.

Although a considerable amount of knowledge has been accumulated about the activity of individual nerve cells in the brain, little is known about their mutual interactions at the local level. The method presented in this paper allows the reconstruction of functional relations within a group of neurons as recorded by a single microelectrode. Data are sampled at 10 or 13 kHz. Prominent spikes produced by one or more single cells are selected and sorted by K-means cluster analysis. The activities of single cells are then related to the background firing of neurons in their vicinity. Auto-correlograms of the leading cells, auto-correlograms of the background cells (mass correlograms) and cross-correlograms between these two levels of firing are computed and evaluated. The statistical probability of mutual interactions is determined, and the statistically significant, most common interspike intervals are stored and attributed to real pairs of spikes in the original record. Selected pairs of spikes, characterized by statistically significant intervals between them, are then assembled into a working model of the system. This method has revealed substantial differences between the information processing in the visual cortex, the inferior colliculus, the rostral ventromedial medulla and the ventrobasal complex of the thalamus. Even short 1-s records of the multiple neuronal activity may provide meaningful and statistically significant results.

The effects of strychnine, bicuculline, and ketamine on 'immersion-inhibited' dorsal horn convergent neurons in intact and spinalized rats.

In both intact and spinalized rats, this study examined the effects of strychnine (a glycine antagonist), bicuculline (a GABAA antagonist), and ketamine (a non-competitive NMDA receptor antagonist) on one particular class of lumbar dorsal horn convergent neurons. This group of convergent neurons are inhibited when a rat's entire ipsilateral hindpaw is immersed in 50 degrees C water and has a strong afterdischarge as soon as the paw is removed from the water. Strychnine (2 mg/kg, iv) increased ongoing activity and blocked the 'inhibition phase' in both intact and spinalized rats demonstrating that a spinal-related glycine mechanism was involved in the inhibition. However, only in intact rats did the firing rate of the 'afterdischarge phase' increase significantly from pre-drug levels, suggesting that supraspinal sites may be involved in modulating this phase. Ketamine (15 mg/kg, iv) depressed ongoing activity and the firing rate in the afterdischarge phase of these neurons. Additionally, ketamine reversed the strychnine-induced increase in ongoing activity. Bicuculline (2 mg/kg, iv) had no effect on the activity of this cell class. As shown previously, and replicated here, these 'immersion-inhibited' neurons invariably have both inhibitory and excitatory mechano-receptive fields on the ipsilateral hindpaw. Thus, the response of this class of convergent neurons to noxious stimulation may be a function of relative inputs of glycine and EAA's, each possibly triggered by the stimulation of different receptive fields/regions on the same paw. Furthermore, when both fields are co-stimulated during noxious immersion of the entire paw, glycine has a stronger influence on activity than does the EAA's.

Two distinct unit activity responses to morphine in the rostral ventromedial medulla of awake rats.

Past research investigating the rostral ventromedial medulla (RVM) in anesthetized animals has found two distinct classes of cells, ON and OFF, noted for their distinct responses to noxious stimuli and to morphine. However, only one class (ON) has been found in the awake animal paradigm. We report in this paper that we have found both the ON and OFF cell responses to morphine in the awake rat.

A-134974: a novel adenosine kinase inhibitor, relieves tactile allodynia via spinal sites of action in peripheral nerve injured rats.

Extracellular levels of adenosine (ADO) can be raised through inhibition of adenosine kinase (AK), a primary metabolic enzyme for ADO. AK inhibitors have shown antinociceptive activity in a variety of animal models of nociception. The present study investigated the antinociceptive actions of a novel and selective AK inhibitor, A-134974 (IC(50)=60 pM), in a rat model of neuropathic pain (ligations of the L5/L6 spinal nerves) and explored the relative contributions of supraspinal, spinal and peripheral sites to the actions of A-134974. Systemic A-134974 dose-dependently reduced tactile allodynia (ED(50)=5 micromol/kg, i.p.) for up to 2 h. Fall latencies in the rotorod test of motor coordination were unaffected by systemic administration of A-134974 (at doses up to 30 micromol/kg, i.p.). Administration of A-134974 intrathecally (i.t.) was more potent (ED(50)=10 nmol) in relieving tactile allodynia than delivering the compound by intracerebroventricular (ED(50)>100 nmol, i.c.v.) or intraplantar (ED(50)>500 nmol) routes suggesting that spinal sites of action are the primary contributors to the anti-allodynic action of A-134974. The anti-allodynic effects of systemic A-134974 (10 micromol/kg, i.p.) were antagonized by the non-selective ADO receptor antagonist, theophylline (30-500 nmol) administered i.t. These data demonstrate that the novel AK inhibitor A-134974 potently reduces tactile allodynia through interactions with spinal sites and adds to the growing evidence that AK inhibitors may be useful as analgesic agents in a broad spectrum of pain states.

Investigating the role of anaesthetics on the rostral ventromedial medulla: implications for a GABAergic link between ON and OFF cells.

Two classes of cells in the rostral ventromedial medulla (RVM), ON and OFF, are important in the descending modulation of noxious input. It is thought that these two cell classes communicate, at a local level, with each other to control the RVM's descending modulation. Systemic morphine was given to rats anaesthetized with either pentobarbital (a GABA agonist) or with ketamine (a non-competitive NMDA receptor antagonist) and xylazine. The spiking activity of the ON and OFF cells was recorded. The typical ON cell inhibition by morphine was observed in rats under both anaesthetics. However, the OFF cell excitatory response to morphine was seen in the ketamine but not in the pentobarbital-anaesthetized animals. The implications for a GABAergic connection between these two classes of cells are discussed.

Effects of noxious hindpaw immersion on evoked and spontaneous firing of contralateral convergent dorsal horn neurons in both intact and spinalized rats.

The effects of immersing a hindpaw in 60 degrees C water for 15 s on spontaneous and pinch-evoked activity recorded from 77 convergent neurons in the contralateral lumbar enlargement were examined. Cells were recorded from intact rats anesthetized with either ketamine or pentobarbital, or in rats that were decerebrated-intact or decerebrated-spinalized to determine if the heterotopic modulation was altered under these different conditions. In 47 neurons with background firing, immersion of the contralateral hindpaw inhibited the on-going activity in 6 of 19 cells recorded from ketamine anesthetized rats, 4 of 12 from pentobarbital anesthetized rats, 7 of 12 from decerebrate-spinalized rats, and 0 of 4 from decerebrate-intact rats. However, this inhibition was variable, both between and within neurons, because not every convergent neuron was inhibited, and there were trials in which immersion had no effect on the on-going activity of a neuron that had been previously inhibited by identical stimulation. In all 77 neurons, across all groups, discharges evoked by pinching the ipsilateral hindpaw were unaffected by contralateral immersion, even in cells where on-going activity was inhibited. Immersion of a hindpaw inhibited on-going, but not evoked, activity of contralateral convergent neurons. This inhibition was observed in rats under varied anesthetic conditions and in spinalized and intact rats. However, not all convergent neurons were inhibited by the remote stimulation even in intact rats, an observation inconsistent with the DNIC model of supraspinally mediated heterotopic modulation. This indicates that the effect of remote noxious stimulation in intact animals is not, under every experimental condition, a widespread inhibition of all convergent neurons.

Heat-excited and heat-inhibited neurones in the ventroposterior nucleus of thalamus of anaesthetized rats.

The activities of 39 single cells, located in the ventroposterior nucleus of the rat thalamus, were recorded from rats deeply anaesthetized with xylazine and ketamine. The activity of each neurone was recorded before and during noxious tail heating. In all, 17 neurones were excited, 11 were inhibited, and 11 were not affected by the noxious stimulation. The possible function of each type of response in the coding of nociceptive information is discussed.

Simultaneous multi- and single-unit recordings in the rostral ventromedial medulla of ketamine-anaesthetized rats, and the cross-correlogram analysis of their interactions.

In anaesthetized rats, neurons located in the rostral ventromedial medulla (RVM) are classified by their differential responses to noxious stimulation. "On" cells are excited by noxious stimulation, "off" cells are inhibited and "neutral" cells are unaffected. Past research has primarily investigated the activity of these cells in lightly barbiturate anaesthetized animals while inducing a tail flick reflex. We recorded neuronal activity in the RVM of deeply ketamine-xylazine anaesthetized rats using a novel method of recording single- and multiunit activity simultaneously with one electrode. Under this anaesthetic paradigm we were able to record RVM cells which responded to noxious tail heating in the same manner as on and off cells without inducing a tail flick. A cross-correlogram analysis was done between the two levels of activity. It demonstrated that the RVM is a highly coordinated system in both the spontaneous period and the noxious evoked activity period. Through this technique it was also shown that both on and off cells fire simultaneously in the ketamine-xylazine paradigm.

A correlogram analysis of the activity in the rostral ventromedial medulla of awake rats and in rats anesthetized with ketamine or pentobarbital following the administration of morphine.

The spiking activity of single units and their corresponding mass activity in the rostral ventromedial medulla (RVM) was recorded simultaneously in rats that were either awake or anesthetized with pentobarbital or ketamine. Autocorrelograms and cross-correlograms were calculated to illustrate the distribution of interspike intervals under each of these conditions. The spontaneous activity in both anesthetized groups, but not the awake group, displayed a low incidence for short intervals (about 1-36 ms) between spikes. However, this low incidence of short interspike intervals was found in some awake rats following the administration of subanesthetic dosages of ketamine, pentobarbital, or morphine. The occurrences, or lack of occurrences of these short interspike intervals may be a marker for the anesthetized state of the rat. A basal spiking pattern, as illustrated by three different types of correlograms, was observed, and these basal patterns did not usually change after the administration of morphine to awake or anesthetized rats, even though the cells became excited or inhibited. Cross-correlograms revealed that the synapses between "on" and "off" cells might sometimes be inhibitory, while at other times they might be excitatory; however, cells of the same class mainly shared excitatory connections. In summary, ketamine and pentobarbital do alter the firing patterns of individual neurons in the RVM, but, no matter what state the rat is in, the activity of individual RVM neurons is strongly related to the activity of other neurons in the local network.

Recent developments in the discovery of novel adenosine kinase inhibitors: mechanism of action and therapeutic potential.

Adenosine (ADO) is an endogenous inhibitory neuromodulator that limits cellular excitability in response to tissue trauma and inflammation. Adenosine kinase (AK; EC 2.7.1.20) is the primary metabolic enzyme regulating intra- and extracellular concentrations of ADO. AK inhibitors have been shown to significantly increase ADO concentrations at sites of tissue injury and to provide effective antinociceptive, antiinflammatory, and anticonvulsant activity in animal models. Structurally novel nucleoside and non-nucleoside AK inhibitors that demonstrate high specificity for the AK enzyme compared with other ADO metabolic enzymes, transporters, and receptors have recently been synthesized. These compounds have also demonstrated improved cellular and tissue penetration compared with earlier tubercidin analogs. These compounds have been shown to exert beneficial effects in animal models of pain, inflammation and epilepsy with reduced cardiovascular side effects compared with direct acting ADO receptor (P1) agonists, thus supporting the hypothesis that AK inhibitors can enhance the actions of ADO in a site- and event-specific fashion.